Menopause: Towards treatment "à la carte";Menopause: Vers un traitement « à la carte »

Annales d'Endocrinologie

Volumn 64, Issue 4, 2003, Pages 337-344

  Bringer, J ^a   Raingeard, I ^a   Lefebvre, P ^a   Renard, E ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Hormone substitution therapy; Menopause; SERMs; Vascular risk

Indexed keywords

ESTRADIOL; PHYTOESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TAMOXIFEN; TIBOLONE;

ADULT; AGED; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLIMACTERIUM; COGNITIVE DEFECT; COLON CANCER; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG EFFICACY; EXERCISE; FEMALE; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; NUTRITION; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK FACTOR; SHORT COURSE THERAPY; STROKE; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VASCULAR DISEASE; VEIN THROMBOSIS; CARDIOVASCULAR DISEASE; COLON TUMOR; ESTROGEN THERAPY; MIDDLE AGED; REPRODUCIBILITY; REVIEW; TIME;

CARDIOVASCULAR DISEASES; COLONIC NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 1542673184     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Barret-Connor, Grady D, Sashegyi A et al. for MORE Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausel women. Four-Year Results From the mORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial. JAMA 2002; 287: 847-857.
2. Bringer J, Raingeard I, Lefebvre P, Renard E. Estrogénothé rapie pulsée: un nouveau concept du traitement hormonal substitutif. Ref Gynecol Obstet 2001; 8: 381-387.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women whithout breast cancer. Lancet 1997; 350: 1047-1059.
4. Cumming SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189-2197.
5. Grady D, Herrington D, Bittner V et al. for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of HRT. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288: 49-57.
6. Gruber J, Tschuggel W, Schneeberger C, Huber JC. Production and actions of estrogens. N. Engl J Med 2002; 346: 340-352.
7. Herrington D, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-529.
8. Herrington D, Howard TD, Hawkins GA et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346: 967-973.
9. Kuipper GG, Gustafsson JA. The novel estrogen receptor-β subtype: potential role in the cell - and promoter - specific actions of estrogens and anti-estrogens. FEBS Lett 1997; 410: 87.
10. Manning PJ. Effet du traitement hormonal substitutif (THS) chez les femmes diabétiques de type 2 sur les protéines de l'inflammation. Diabet Med 2002; 19: 847-852.
11. Palacios S. Tibolone: Que signifie l'activité tissu-spé cifique? Ref Gynecol Obstet 2001; 8: 339-343.
12. Pujol P, Rey JM, Nirde P et al. Differential expression of estrogen receptor α et β as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58: 5367-5373.
13. Pujol P, Th. Maudelonde. SERM: Concept et mécanismes d'action. La lettre du gynécologue 2001; 258: 29-36.
14. Riggs BL. Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2417-2418.
15. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of HRT on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-332.
16. Rouayrenc JF, Vignon F, Bringer J, Pujol P. Les effets non-transcriptionnels des estrogènes refont surface. Annales d'Endocrinologie 2001; 61: 517-523.
17. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-491.
18. Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA, 2003; 289: 2651-2662.
19. Studd J, Pornel B, Marton I et al. Efficacy and acceptibility of intranasal 17 b-estradiol for menopausal symptoms: randomised dose-response study. Lancet 1999; 853: 1574-1578.
20. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. New Engl J Med 2001; 345: 1243-1249.
21. Wassertheil-Smoller S, Hendrix SL, Limacher M. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA, 2003; 289: 2673-2684.
22. Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the WHI randomies controlled trial. JAMA 2002; 288: 321-333.
23. Yaffe K - Hormone therapy and the brain. JAMA, 2003; 289: 2717-2719.
24. Yochum L, Kushi LH, Meyer K, Folsom AR. Dietary flavonoid intake and risks of cardiovascular disease in post-menopausal women. Am J Epidemiol 1999; 149: 943-949.
25. Zhu Y, Bian Z, Karas RH et al. Abnormal vascular function and hypertension in mice dificient in estrogen receptor β. Science 2002; 295: 505-508.